Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPECT-COVID
2020-005884-29Phase 3Terminated
- Sponsor
- University of Perugia
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of low molecular weight heparin calcium in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Perugia. Primary endpoint: Primary composite endpoint. Started Jun 2021; status: terminated.
02
Drugs
low molecular weight heparin calcium
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005884-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005884-29.